Amicus’s Strategic Market Expansion and Strong Financial Outlook Drive Buy Rating

Wells Fargo analyst Tiago Fauth maintained a Buy rating on Amicus (FOLD – Research Report) yesterday and set a price target of $17.00.

Tiago Fauth has given his Buy rating due to a combination of factors including Amicus’s strategic focus on the PomOp launch, which is viewed as a major growth driver for the company. Amicus has already secured regulatory approval for PomOp in Australia and expects additional approvals in Japan and Canada in 2025, significantly expanding their market reach. This expansion into new markets is expected to drive substantial revenue growth, as indicated by the 65-85% constant exchange rate growth guidance for PomOp in 2025.
Amicus’s financial outlook remains strong, with no surprises in their top-line numbers due to prior announcements. The company has projected a robust overall revenue growth of 17-24% for 2025, supported by a high gross margin and managed operating expenses. The company’s strategic initiatives and financial projections, alongside their execution in launching and reimbursement strategies, underpin Tiago Fauth’s positive outlook and Buy rating for Amicus’s stock.

According to TipRanks, Fauth is a 3-star analyst with an average return of 1.0% and a 43.08% success rate. Fauth covers the Healthcare sector, focusing on stocks such as Amicus, Insmed, and PTC Therapeutics.

In another report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $14.00 price target.